Case Commentary: Emergence of clinically relevant fidaxomicin-resistant Clostridioides difficile strains
Antimicrobial Agents and Chemotherapy · 2026
DOI: 10.1128/aac.00482-26 ↗Kurz gefasst
Editorial in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Kevin W Garey und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, Texas, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Clostridioides difficile, Clostridium Infections, Fidaxomicin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Clostridioides difficile infection (CDI) has limited antibiotic treatment options, with fidaxomicin being the guideline-preferred antibiotic. C. E. Kaple, S. N. Redmond, J. L. Cadum, B. Hausman, et al. (Antimicrob Agents Chemother 0:e00130-26, 2026, https://doi.org/10.1128/aac.00130-26 ) describe a case of clinical failure in an elderly patient with CDI treated with a pulsed-taper fidaxomicin regimen, in which the MIC increased from 0.05 μg/mL at baseline to 32 μg/mL in isolates recovered during relapse. Relapsing symptoms were eventually resolved only after switching to oral vancomycin. This case, together with other recent clinical reports, may be the tip of the iceberg, signaling that fidaxomicin-resistant C. difficile can arise during treatment and contribute to clinical failure. It further challenges the assumption that high colonic drug concentrations mitigate resistance and underscores the need for improved surveillance and the development of clinically applicable molecular diagnostics to detect fidaxomicin resistance in CDI patient samples.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, Texas, USA.
- Center for Infectious and Inflammatory Diseases, Institute of Biosciences and Technology, Houston, Texas, USA.
- Department of Translational Medical Sciences, Naresh K. Vashisht College of Medicine, Texas A&M University, Houston, Texas, USA.
ORCID-Profile: Kevin W Garey, Julian G Hurdle
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Garey, K. W., & Hurdle, J. G. (2026). Case Commentary: Emergence of clinically relevant fidaxomicin-resistant Clostridioides difficile strains. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00482-26
Vancouver
Garey KW, Hurdle JG. Case Commentary: Emergence of clinically relevant fidaxomicin-resistant Clostridioides difficile strains. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.00482-26
BibTeX
@article{Garey2026,
author = {Garey, Kevin W and Hurdle, Julian G},
title = {Case Commentary: Emergence of clinically relevant fidaxomicin-resistant Clostridioides difficile strains},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
doi = {10.1128/aac.00482-26}
}
EUVIMED